

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 1 | 3 | — | — | — | 3 |
| Paraproteinemias | D010265 | — | D47.2 | 1 | 1 | — | — | — | 1 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | 1 | — | — | — | 1 |
| Plasma cell leukemia | D007952 | — | C90.1 | 1 | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 1 |
| Drug common name | FILANESIB |
| INN | filanesib |
| Description | Filanesib (code name ARRY-520) is a kinesin spindle protein (KIF11) inhibitor which has recently been proposed as a cancer treatment, specifically for multiple myeloma.
|
| Classification | Small molecule |
| Drug class | kinesin inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1 |
| PDB | — |
| CAS-ID | 130996-24-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2347655 |
| ChEBI ID | — |
| PubChem CID | 44224257 |
| DrugBank | — |
| UNII ID | 8A49OSO368 (ChemIDplus, GSRS) |

